Related references
Note: Only part of the references are listed.Multiple comparisons: a tutorial. Part 1. Understanding hypothesis testing
Michael T. Lawson et al.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY (2021)
The interplay between epigenetic changes and the p53 protein in stem cells
Arnold J. Levine et al.
GENES & DEVELOPMENT (2017)
Estrogen Receptor β as a Therapeutic Target in Breast Cancer Stem Cells
Ran Ma et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Estrogen Receptor β as a Therapeutic Target in Breast Cancer Stem Cells
Ran Ma et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Estrogen Receptor-β Modulation of the ERα-p53 Loop Regulating Gene Expression, Proliferation, and Apoptosis in Breast Cancer
Wenwen Lu et al.
HORMONES & CANCER (2017)
Putting p53 in Context
Edward R. Kastenhuber et al.
CELL (2017)
ERβ overexpression results in endocrine therapy resistance and poor prognosis in postmenopausal ERα-positive breast cancer patients
Liying Guo et al.
ONCOLOGY LETTERS (2016)
ERβ decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function
Igor Bado et al.
ONCOTARGET (2016)
Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ
Ameet K. Mishra et al.
ONCOTARGET (2016)
Immunohistochemical correlates of TP53 somatic mutations in cancer
Balazs Murnyak et al.
ONCOTARGET (2016)
Mutant p53 Drives Cancer by Subverting Multiple Tumor Suppression Pathways
Sue Haupt et al.
FRONTIERS IN ONCOLOGY (2016)
p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer
Emily Powell et al.
BREAST CANCER RESEARCH (2016)
Functional interplay between MDM2, p63/p73 and mutant p53
M. H. Stindt et al.
ONCOGENE (2015)
ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer
Jordan M. Reese et al.
BMC CANCER (2014)
TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance
Laxmi Silwal-Pandit et al.
CLINICAL CANCER RESEARCH (2014)
Support of a bi-faceted role of estrogen receptor β (ERβ) in ERα-positive breast cancer cells
Philip Jonsson et al.
ENDOCRINE-RELATED CANCER (2014)
Estrogen receptor beta in breast cancer
Lars-Arne Haldosen et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2014)
Expression of both Estrogen Receptor-beta 1 (ER-β1) and its co-regulator Steroid Receptor RNA Activator Protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with Estrogen Receptor-alpha (ER-α)-Negative Early Breast Cancer (EBC)
Y. Yan et al.
ANNALS OF ONCOLOGY (2013)
A bi-faceted role of estrogen receptor β in breast cancer
Etienne Leygue et al.
ENDOCRINE-RELATED CANCER (2013)
The rebel angel: mutant p53 as the driving oncogene in breast cancer
Dawid Walerych et al.
CARCINOGENESIS (2012)
Mutant p53: one name, many proteins
William A. Freed-Pastor et al.
GENES & DEVELOPMENT (2012)
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models
Cynthia X. Ma et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Targeting Mutant p53 in Human Tumors
Brian D. Lehmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Sohrab P. Shah et al.
NATURE (2012)
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
Christina Curtis et al.
NATURE (2012)
Estrogen receptor prevents p53-dependent apoptosis in breast cancer
Shannon T. Bailey et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Estrogen receptor-beta and breast cancer: Translating biology into clinical practice
Yuet-Kin Leung et al.
STEROIDS (2012)
Estrogen receptor beta decreases survival of p53-defective cancer cells after DNA damage by impairing G2/M checkpoint signaling
Christoforos G. Thomas et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Mutant p53 Disrupts MCF-10A Cell Polarity in Three-dimensional Culture via Epithelial-to-mesenchymal Transitions
Yanhong Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis
Anna Yemelyanova et al.
MODERN PATHOLOGY (2011)
Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen
Xianglin Wu et al.
BREAST CANCER RESEARCH (2011)
Estrogen receptor-β expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study
Jonathan D. Marotti et al.
MODERN PATHOLOGY (2010)
Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation
Santhi D. Konduri et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Estrogen receptor acting in cis enhances WT and mutant p53 transactivation at canonical and noncanonical p53 target sequences
Daniel Menendez et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Mutant p53 Gain-of-Function in Cancer
Moshe Oren et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
Disruption of estrogen receptor α-p53 interaction in breast tumors: a novel mechanism underlying the anti-tumor effect of radiation therapy
Wensheng Liu et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Estrogen receptor beta in breast cancer-Diagnostic and therapeutic implications
Johan Hartman et al.
STEROIDS (2009)
Clinical importance of estrogen receptor-β evaluation in breast cancer patients treated with adjuvant tamoxifen therapy
Naoko Honma et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Estrogen receptor alpha negative breast cancer patients: Estrogen receptor beta as a therapeutic target
George P. Skliris et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2008)
Oestrogen receptors α and β show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer
S. Borgquist et al.
JOURNAL OF CLINICAL PATHOLOGY (2008)
A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study
Flavia Novelli et al.
BREAST CANCER RESEARCH (2008)
Estrogen receptor α inhibits p53-mediated transcriptional repression:: Implications for the regulation of apoptosis
Aejaz Sayeed et al.
CANCER RESEARCH (2007)
Estrogen receptor beta expression is associated with tamoxifen response in ER alpha-negative breast carcinoma
Sofia K. Gruvberger-Saal et al.
CLINICAL CANCER RESEARCH (2007)
Direct observation of individual endogenous protein complexes in situ by proximity ligation
Ola Soderberg et al.
NATURE METHODS (2006)
Expression of oestrogen receptor-β in oestrogen receptor-α negative human breast tumours
G. P. Skliris et al.
BRITISH JOURNAL OF CANCER (2006)
Estrogen receptor-α binds p53 tumor suppressor protein directly and represses its function
WS Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Estrogen receptors as therapeutic targets in breast cancer
Eric A. Ariazi et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2006)
p73 functionally replaces 1353 in Adriamycin-treated, p53-deficient breast cancer cells
M Vayssade et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
E1A activates transcription of p73 and noxa to induce apoptosis
M Flinterman et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Estrogen receptors ERα and ERβ in proliferation in the rodent mammary gland
GJ Cheng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
p73 induces apoptosis via PUMA transactivation and Bax mitochondrial translocation
G Melino et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Estrogen receptor β inhibits 17β-estradiol-stimulated proliferation of the breast cancer cell line T47D
A Ström et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Estrogen receptor β (ERβ) level but not its ERβcx variant helps to predict tamoxifen resistance in breast cancer
M Esslimani-Sahla et al.
CLINICAL CANCER RESEARCH (2004)
Low levels of estrogen receptor β protein predict resistance to tamoxifen therapy in breast cancer
TA Hopp et al.
CLINICAL CANCER RESEARCH (2004)
Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G(2) cell cycle arrest
S Paruthiyil et al.
CANCER RESEARCH (2004)
Wild-type oestrogen receptor beta (ERb1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers
PA O'Neill et al.
BRITISH JOURNAL OF CANCER (2004)
The favourable prognostic value of oestrogen receptor β immunohistochemical expression in breast cancer
L Nakopoulou et al.
JOURNAL OF CLINICAL PATHOLOGY (2004)
p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis
D Bergamaschi et al.
CANCER CELL (2003)
Tamoxifen: A most unlikely pioneering medicine
VC Jordan
NATURE REVIEWS DRUG DISCOVERY (2003)
Estrogen receptors and proliferation markers in primary and recurrent breast cancer
EV Jensen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Wild type p73 overexpression and high-grade malignancy in breast cancer
G Dominguez et al.
BREAST CANCER RESEARCH AND TREATMENT (2001)
Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers:: Prevalence of alterations in inflammatory breast cancers
JC Ahomadegbe et al.
ONCOGENE (2000)
A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model
KL Murphy et al.
FASEB JOURNAL (2000)
Physical and functional interaction between p53 mutants and different isoforms of p73
S Strano et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Nora, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis
E Oda et al.
SCIENCE (2000)
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
MC Marin et al.
NATURE GENETICS (2000)
Estrogen receptors α and β in the rodent mammary gland
S Saji et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
